Home > Products > All > CIPROFLOXACIN Injection, USP*
Product Image
Please see full prescribing and safety information, including boxed warning, for CIPROFLOXACIN bags. PACKAGE INSERT (114-82, 114-87) | MEDICATION GUIDE(114-82,114-87) PACKAGE INSERT (192-82, 192-87)| MEDICATION GUIDE(192-82,192-87)

Available in:

  • 200 mg per 100 mL in 5% Dextrose premix bags
  • 400 mg per 200 mL in 5% Dextrose premix bags

Benefits:

  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex

Downloads:

PreventIV

CIPROFLOXACIN Injection, USP*

Brand Name Equivalent: CIPRO® (CIPRO is a registered trademark of Bayer Aktiengesellschaft Joint Stock Company)
Therapeutic Category: Anti-Infective

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Drug name and strength printed on front and back of overwrap
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
NDC
#25021		 Description Strength Fill
Volume 		Concentration Container
Size 		Closure Unit
of Sale
114-82 Premix Bag 200 mg 100 mL 2 mg per mL NA NA 24
192-82* Premix Bag 200 mg 100 mL 2 mg per mL N/A N/A 24
114-87 Premix Bag 400 mg 200 mL 2 mg per mL N/A N/A 24
192-87* Premix Bag 400 mg 200 mL 2 mg per mL N/A N/A 24
* DEHP-Free, PVC-Free
WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF  MYASTHENIA GRAVIS
Fluoroquinolones, including Ciprofloxacin Injection (in 5%Dextrose Injection), have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1)] including:
  • Tendinitis and tendon rupture [see Warnings and Precautions (5.2)]
  • Peripheral neuropathy [see Warnings and Precautions (5.3)] Central nervous system effects [see Warnings and Precautions (5.4)]
Discontinue Ciprofloxacin Injection (in 5% Dextrose Injection) immediately and avoid the use of fluoroquinolones, including Ciprofloxacin Injection (in 5% Dextrose Injection), in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1)]. Fluoroquinolones, including Ciprofloxacin Injection (in 5%Dextrose Injection), may exacerbate muscle weakness in patients with myasthenia gravis. Avoid Ciprofloxacin Injection in patients with known history of myasthenia gravis [see Warnings and Precautions (5.5)]. Because fluoroquinolones, including Ciprofloxacin Injection (in 5% Dextrose Injection), have been associated with serious adverse reactions [see Warnings and Precautions (5.1 to 5.16)], reserve Ciprofloxacin Injection (in 5% Dextrose Injection) for use in patients who have no alternative treatment options for the following indications:
  • Acute exacerbation of chronic bronchitis [see Indications and Usage (1.9)]
  • Acute Sinusitis [see Indications and Usage (1.11)]